AP
TAK icon

Arlington Partners’s Takeda Pharmaceutical TAK Stock Holding History

Arlington Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20
Closed – – 407
2021
Q2 		$0 Hold
20
– – ﹤0.01% 377
2021
Q1 		$0 Buy
+20
New +$360 ﹤0.01% 410
2020
Q2 		– Sell
-197
Closed -$3K – 278
2020
Q1 		$3K Buy
+197
New +$3.57K ﹤0.01% 232

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arlington Partners's TAK Position: Q3 2021 in Review

Arlington Partners sold out of Takeda Pharmaceutical (TAK) in Q3 2021, closing a stake of 20 shares.

Arlington Partners first reported a position in TAK in Q1 2020 and held it in 3 quarters. The position peaked at $3K in Q1 2020. 292 funds tracked by Wall St. Rank hold TAK as of Q3 2021.

  • Arlington Partners reported no remaining Takeda Pharmaceutical position as of Q3 2021 after selling out during the quarter.
  • Arlington Partners sold 20 Takeda Pharmaceutical shares in Q3 2021.
  • Arlington Partners first reported a position in Takeda Pharmaceutical in Q1 2020 and held it in 3 quarters.
  • Arlington Partners's Takeda Pharmaceutical position peaked at $3K in Q1 2020.
  • 292 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2021.

Based on Arlington Partners's 13F filing for Q3 2021, filed 15 Oct 2021.